Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for CR-003 (Topoisomerase Inhibitor ADC) in Solid Tumors. The expected timing is based on the latest available company guidance and may change.
07/30/26:- China Ph1/2 ongoing; PoC Q1 2027. CR-001 combo starts H1 2027; data Year-End 2027.
Verification
Confirm timing and program details against the company announcement or filing.